Robert C.A.M. van Waardenburg - Search Results

Year	Number of Results
2002	1
2003	1
2004	3
2005	1
2006	1
2007	2
2011	1
2012	1
2014	1
2015	1
2016	2
2017	2
2018	3
2019	3
2021	3
2022	2
2023	2
2024	0

1

DNA topoisomerase-targeting chemotherapeutics: what's new?

Cuya SM, Bjornsti MA, van Waardenburg RCAM. Cuya SM, et al. Among authors: van waardenburg rcam. Cancer Chemother Pharmacol. 2017 Jul;80(1):1-14. doi: 10.1007/s00280-017-3334-5. Epub 2017 May 20. Cancer Chemother Pharmacol. 2017. PMID: 28528358 Free PMC article. Review.

2

Targeting DNA topoisomerases: past & future.

Gmeiner WH, van Waardenburg RCAM. Gmeiner WH, et al. Among authors: van waardenburg rcam. Cancer Drug Resist. 2021;4(4):758-761. doi: 10.20517/cdr.2021.65. Epub 2021 Jul 21. Cancer Drug Resist. 2021. PMID: 34532656 Free PMC article. No abstract available.

3

Tyrosyl-DNA Phosphodiesterase I N-Terminal Domain Modifications and Interactions Regulate Cellular Function.

Brettrager EJ, Segura IA, van Waardenburg RCAM. Brettrager EJ, et al. Among authors: van waardenburg rcam. Genes (Basel). 2019 Nov 6;10(11):897. doi: 10.3390/genes10110897. Genes (Basel). 2019. PMID: 31698852 Free PMC article. Review.

4

Human cytosolic steroid sulfotransferases: Versatile and rapid activity assays.

Falany CN, Garcia PL, Hossain MI, van Waardenburg RCAM. Falany CN, et al. Among authors: van waardenburg rcam. Methods Enzymol. 2023;689:332-352. doi: 10.1016/bs.mie.2023.04.008. Epub 2023 Aug 4. Methods Enzymol. 2023. PMID: 37802577

5

Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.

van Waardenburg RC, de Jong LA, van Eijndhoven MA, Verseyden C, Pluim D, Jansen LE, Bjornsti MA, Schellens JH. van Waardenburg RC, et al. J Biol Chem. 2004 Dec 24;279(52):54502-9. doi: 10.1074/jbc.M410103200. Epub 2004 Oct 6. J Biol Chem. 2004. PMID: 15471886 Free article.

6

Tyrosyl-DNA phosphodiesterase I resolves both naturally and chemically induced DNA adducts and its potential as a therapeutic target.

Comeaux EQ, van Waardenburg RC. Comeaux EQ, et al. Among authors: van waardenburg rc. Drug Metab Rev. 2014 Nov;46(4):494-507. doi: 10.3109/03602532.2014.971957. Epub 2014 Oct 20. Drug Metab Rev. 2014. PMID: 25327705 Review.

7

Sulfotransferase 4A1 activity facilitates sulfate-dependent cellular protection to oxidative stress.

Brettrager EJ, Meehan AW, Falany CN, van Waardenburg RCAM. Brettrager EJ, et al. Among authors: van waardenburg rcam. Sci Rep. 2022 Jan 31;12(1):1625. doi: 10.1038/s41598-022-05582-4. Sci Rep. 2022. PMID: 35102205 Free PMC article.

8

N-terminal domain of tyrosyl-DNA phosphodiesterase I regulates topoisomerase I-induced toxicity in cells.

Brettrager EJ, Cuya SM, Tibbs ZE, Zhang J, Falany CN, Aller SG, van Waardenburg RCAM. Brettrager EJ, et al. Among authors: van waardenburg rcam. Sci Rep. 2023 Jan 25;13(1):1377. doi: 10.1038/s41598-023-28564-6. Sci Rep. 2023. PMID: 36697463 Free PMC article.

9

Sphingolipid metabolism and drug resistance in ovarian cancer.

Kreitzburg KM, van Waardenburg RCAM, Yoon KJ. Kreitzburg KM, et al. Among authors: van waardenburg rcam. Cancer Drug Resist. 2018;1:181-197. doi: 10.20517/cdr.2018.06. Epub 2018 Sep 19. Cancer Drug Resist. 2018. PMID: 31891125 Free PMC article.

10

Targeting DNA repair pathways to overcome cancer drug resistance.

van Waardenburg RCAM, Yang ES. van Waardenburg RCAM, et al. Cancer Drug Resist. 2021;4(4):837-841. doi: 10.20517/cdr.2021.80. Epub 2021 Aug 19. Cancer Drug Resist. 2021. PMID: 34532658 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

28 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year